본문 바로가기
KERD
논문KCI 등재

Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2

어성국|Junu A. George
대한면역학회 (The Korean Association of Immunologists)|2011.10|Immune Network|제11권 제5호|pp. 268-280

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

DNA vaccineVaccinia virusRecombinant adenovirusDengue virus type 2E proteinPrime-boost vaccination

초록

Background: Dengue virus, which belongs to the Flavivirus genus of the Flaviviridae family, causes fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with infection risk of 2.5 billion people worldwide. However, approved vaccines are still not available. Here, we explored the immune responses induced by alternating prime-boost vaccination using DNA vaccine, adenovirus, and vaccinia virus expressing E protein of dengue virus type 2 (DenV2). Methods:Following immunization with DNA vaccine (pDE), adenovirus (rAd-E), and/or vaccinia virus (VV-E) expressing E protein, E protein-specific IgG and its isotypes were determined by conventional ELISA. Intracellular CD154 and cytokine staining was used for enumerating CD4＋ T cells specific for E protein. E protein-specific CD8＋ T cell responses were evaluated by in vivo CTL killing activity and intracellular IFN-γstaining. Results: Among three constructs, VV-E induced the most potent IgG responses, Th1-type cytokine production by stimulated CD4＋ T cells, and the CD8＋ T cell response. Furthermore, when the three constructs were used for alternating prime-boost vaccination, the results revealed a different pattern of CD4＋ and CD8＋ T cell responses. i) Priming with VV-E induced higher E-specific IgG level but it was decreased rapidly. ii) Strong CD8＋ T cell responses specific for E protein were induced when VV-E was used for the priming step, and such CD8＋ T cell responses were significantly boosted with pDE. iii) Priming with rAd-E induced stronger CD4＋ T cell responses which subsequently boosted with pDE to a greater extent than VV-E and rAd-E. Conclusion: These results indicate that priming with live viral vector vaccines could induce different patterns of E protein-specific CD4＋ and CD8＋ T cell responses which were significantly enhanced by booster vaccination with the DNA vaccine. Therefore, our observation will provide valuable information for the establishment of optimal prime-boost vaccination against DenV.

Abstract

Background: Dengue virus, which belongs to the Flavivirus genus of the Flaviviridae family, causes fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with infection risk of 2.5 billion people worldwide. However, approved vaccines are still not available. Here, we explored the immune responses induced by alternating prime-boost vaccination using DNA vaccine, adenovirus, and vaccinia virus expressing E protein of dengue virus type 2 (DenV2). Methods:Following immunization with DNA vaccine (pDE), adenovirus (rAd-E), and/or vaccinia virus (VV-E) expressing E protein, E protein-specific IgG and its isotypes were determined by conventional ELISA. Intracellular CD154 and cytokine staining was used for enumerating CD4＋ T cells specific for E protein. E protein-specific CD8＋ T cell responses were evaluated by in vivo CTL killing activity and intracellular IFN-γstaining. Results: Among three constructs, VV-E induced the most potent IgG responses, Th1-type cytokine production by stimulated CD4＋ T cells, and the CD8＋ T cell response. Furthermore, when the three constructs were used for alternating prime-boost vaccination, the results revealed a different pattern of CD4＋ and CD8＋ T cell responses. i) Priming with VV-E induced higher E-specific IgG level but it was decreased rapidly. ii) Strong CD8＋ T cell responses specific for E protein were induced when VV-E was used for the priming step, and such CD8＋ T cell responses were significantly boosted with pDE. iii) Priming with rAd-E induced stronger CD4＋ T cell responses which subsequently boosted with pDE to a greater extent than VV-E and rAd-E. Conclusion: These results indicate that priming with live viral vector vaccines could induce different patterns of E protein-specific CD4＋ and CD8＋ T cell responses which were significantly enhanced by booster vaccination with the DNA vaccine. Therefore, our observation will provide valuable information for the establishment of optimal prime-boost vaccination against DenV.

참고문헌 (51)

  1. Swaminathan S, "Dengue: recent advances in biology and current status of translational research", Curr Mol Med, 9, pp.152~173 (2009)
  2. Guha-Sapir D, "Dengue fever: new paradigms for a changing epidemiology", Emerg Themes Epidemiol, 2, pp.1~ (2005)
  3. Halstead SB, "Dengue", Lancet, 370, pp.1644~1652 (2007)
  4. Rothman AL, "Dengue: defining protective versus pathologic immunity", J Clin Invest, 113, pp.946~951 (2004)
  5. Stephenson JR, "Understanding dengue pathogenesis: implications for vaccine design", Bull World Health Organ, 83, pp.308~814 (2005)
  6. Kanesa-thasan N, "Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers", Vaccine, 19, pp.3179~3188 (2001)
  7. Edelman R, "Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine", Am J Trop Med Hyg, 69(6), pp.48~60 (2003)
  8. Kitchener S, "Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults", Vaccine, 24, pp.1238~1241 (2006)
  9. Sun W, "Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults", Hum Vaccin, 5, pp.33~40 (2009)
  10. Kelly EP, "Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice", Vaccine, 18, pp.2549~2559 (2000)
  11. Muné M, "Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice", Arch Virol, 148, pp.2267~2273 (2003)
  12. Hermida L, "A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice", Biotechnol Appl Biochem, 39, pp.107~114 (2004)
  13. Hermida L, "A recombinant fusion protein containing the domain III of the dengue- 2 envelope protein is immunogenic and protective in nonhuman primates", Vaccine, 24, pp.3165~3171 (2006)
  14. Blaney JE Jr, "Genetically modified, live attenuated dengue virus type 3 vaccine candidates", Am J Trop Med Hyg, 71, pp.811~821 (2004)
  15. Blaney JE Jr, "Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys", J Virol, 79, pp.5516~5528 (2005)
  16. Suzuki R, "Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2", J Virol, 83, pp.1870~1880 (2009)
  17. Azevedo AS, "DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III", PLoS One, 6, pp.e20528~ (2011)
  18. Konishi E, "Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model", Microbes Infect, 13, pp.1091~1098 (2011)
  19. Whitehorn J, "The pathogenesis of dengue", Vaccine, 29, pp.7221~7228 (2011)
  20. Halstead SB, "The future of dengue vaccines", Lancet, 360, pp.1243~1245 (2002)
  21. Hombach J, "Vaccines against dengue: a review of current candidate vaccines at advanced development stages", Rev Panam Salud Publica, 21, pp.254~260 (2007)
  22. Guy B, "Towards a dengue vaccine: progress to date and remaining challenges", Comp Immunol Microbiol Infect Dis, 31, pp.239~252 (2008)
  23. Anderson KB, "Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate", J Infect Dis, 204, pp.442~450 (2011)
  24. Simmons M, "Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy", Virology, 396, pp.280~288 (2010)
  25. Paris RM, "Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1", Expert Rev Vaccines, 9, pp.1055~1069 (2010)
  26. Hill AV, "Prime-boost vectored malaria vaccines: progress and prospects", Hum Vaccin, 6, pp.78~83 (2010)
  27. Vázquez-Blomquist D, "Modifiedvaccinia- virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8＋ T-cell response in mice against an HIV-1 epitope than does a DNA", poxvirus prime-booster approach, 2004, pp.39, 313~318
  28. Lu J, "Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein", Clin Dev Immunol, 2011, pp.617892~ (2011)
  29. Schneider J, "Enhanced immunogenicity for CD8＋ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara", Nat Med, 4, pp.397~402 (1998)
  30. Rollier C, "Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting", J Infect Dis, 192, pp.920~929 (2005)
  31. Wu L, "Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens", J Virol, 79, pp.8024~8031 (2005)
  32. Barouch DH, "Adenovirus vector-based vaccines for human immunodeficiency virus type 1", Hum Gene Ther, 16, pp.149~156 (2005)
  33. Tritel M, "Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses", J Immunol, 171, pp.2538~2547 (2003)
  34. Men R, "Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge", Vaccine, 18, pp.3113~3122 (2000)
  35. Eo SK, "Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines", J Virol, 75, pp.569~578 (2001)
  36. Walhout AJ, "GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes", Methods Enzymol, 328, pp.575~592 (2000)
  37. Chakrabarti S, "Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques", Mol Cell Biol, 5, pp.3403~3409 (1985)
  38. Graziani-Bowering GM, "A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes", J Immunol Methods, 207, pp.157~168 (1997)
  39. Frentsch M, "Direct access to CD4＋ T cells specific for defined antigens according to CD154 expression", Nat Med, 11, pp.1118~1124 (2005)
  40. Chattopadhyay PK, "live-cell assay to detect antigen-specific CD4＋ T cells with diverse cytokine profiles", Nat Med, 11, pp.1113~1117 (2005)
  41. 한영우, "Multifront Assault on Antigen Presentation by Japanese Encephalitis Virus Subverts CD8(+) T Cell Responses", JOURNAL OF IMMUNOLOGY, 185(3), pp.1429~1441, AMER ASSOC IMMUNOLOGISTS
  42. Lakhashe SK, "Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges", Vaccine, 29, pp.5611~5622 (2011)
  43. De Rosa SC, "National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network: HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable", J Immunol, 187, pp.3391~3401 (2011)
  44. 김선주, "Multiple Alternating Immunizations with DNA Vaccine and Replicationincompetent Adenovirus Expressing gB of Pseudorabies Virus Protect Animals Against Lethal Virus Challenge", Journal of Microbiology and Biotechnology, 18(7), pp.1326~1334 (2008), 한국미생물·생명공학회
  45. DiNapoli JM, "Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response", Vaccine, 29, pp.17~25 (2010)
  46. Pan Z, "Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus", Clin Vaccine Immunol, 17, pp.518~523 (2010)
  47. Ding H, "Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus", PLoS One, 6, pp.e16563~ (2011)
  48. Eo SK, "Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules", J Immunol, 166, pp.5473~5479 (2001)
  49. Nguyen TV, "High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen", Clin Vaccine Immunol, 13, pp.475~485 (2006)
  50. Neeson P, "A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype", Virology, 354, pp.299~315 (2006)
  51. Sandau MM, "IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool", J Immunol, 184, pp.35~44 (2010)

관련 논문AI추천

Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys남효정, 박수형, 성영철, 송미영, 임세진대한면역학회 · Immune Network2010 · 제10권 제6호Efficient Induction of Th1-type Immune Responses to Hepatitis B Virus Antigens by DNA Prime-Adenovirus Boost박수형, 성영철, 송만기, 양세환, 이창근, 최소영대한면역학회 · Immune Network2005 · 제5권 제1호Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in Mice신옥, 김우주, 노지윤, 송준영, 이한솔, 이효진, 정문섭, 정희진, 최은진대한감염학회 · Infection and Chemotherapy2017 · 제49권 제2호Epitope발현 DNA vaccine과 recombinant vaccinia virus를 이용한 heterologous prime-boost vaccination에 의하여 유도되는 CD8+ T 세포 매개성 면역박성옥, 어성국, 윤현아, 이존화, 채준석, Abi George Aleyas대한면역학회 · Immune Network2005 · 제5권 제2호CD8+ T-cell Activation in Mice Injected with a Plasmid DNA Vaccine Encoding AMA-1 of the Reemerging Korean Plasmodium vivax김태우, 김태윤, 신은희, 정봉광, 채종일, 최병일, Hajime Hisaeda, Hyo-Jin Kim, Jin-Joo Lee, Kunisuke Himeno, Kyoung-Ho Pyo대한기생충학ㆍ열대의학회 · Parasites, Hosts and Diseases2011 · 제49권 제1호Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene장준, 서유석, 성영철, 조재호, 진현탁, 최소영대한면역학회 · Immune Network2009 · 제9권 제5호

이 간행물의 다른 논문 (8건)

MicroRNAs in Human Diseases: From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases하대유pp. 227-244Antimicrobial Peptides in Innate Immunity against Mycobacteria신동민, 조은경pp. 245-252Vitamin D Receptor Gene TaqI, BsmI and FokI Polymorphisms in Korean Patients with Tuberculosis신은순, 김관형, 채규태, 염정은, 김치홍, 이성범, 진송우, 이상학, 강태진pp. 253-257Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis심승철, 이민지, 이소영, 신동혁, 김찬, 양윤식, 임미경, 이상광, 김지영pp. 258-267Nanoliposomes of L-lysine-conjugated poly(aspartic acid) Increase the Generation and Function of Bone Marrowderived Dendritic Cells김기향, 지홍근, 박선기, 이종길, 유형경, 임선아pp. 281-287
원문 보기